Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Court ends exclusivity absurdity

Posted 15 June 2021 AM

In a decision that could have wide-reaching implications for the pharma industry, the Federal Court has ordered the Commisioner of Patents to grant BMS a patent term extension (PTE) for its blockbuster cancer drug Opdivo that pushes out to 2031.

The sternly worded judgment delivered by Justice Jonathan Beach said the Commissioner's interpretation of legislation - the basis on which the extension was refused - leads to "manifest absurdity or unreasonableness". 

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pitfalls may plague NMP review
With an election in play, will it arrive too late?
Approvals Action
First copy of Halaven ticked
Along with other generics of already PBS-listed drugs